Bill Detail

S. 1096

Congress: 119

Title

Preserve Access to Affordable Generics and Biosimilars Act

Summary

Preserve Access to Affordable Generics and Biosimilars Act This bill prohibits parties from entering into any agreement that resolves or settles a patent claim related to the sale of a drug or biological product and that has anticompetitive effects. Such an agreement is presumed to have anticompetitive effects if the filer of a generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar. An agreement is exempt if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a U.S. patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects. The bill provides for enforcement by the Federal Trade Commission (FTC). Violators are subject to penalties including the forfeiture of the 180-day marketing exclusivity period for a generic drug. Additionally, when a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC and the Department of Justice concerning the agreement contains the complete agreement and any related agreements, including descriptions of any oral agreements or representations.

Sponsor

Sen. Amy Klobuchar [D-MN]

Status

Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.

Status as of Nov 16, 2026, 3:28 PM · synced 19h ago

Introduced

2025-03-24

Data source mode: cache

Bill Engagement

Lobbyists on the case

9 orgs · 114 lobbyists · 18 filings mention S. 1096 (Preserve Access to Affordable Generics and Biosimilars Act) in LDA disclosures.

These are cached disclosure mentions, not verified current representation or confirmed event attendance.

Top orgs filing

Limited preview · paid intelligence

Keep the intelligence current—not just this one record.

Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.

Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.

Buy Federal Intelligence · $2,500 for 3 monthsRequest a Sample by EmailPrefer a walkthrough first?Already a customer? Sign inGet free intelligence alerts →

After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.